Benralizumab Approved by FDA as Self-Administered Auto-Injector for Asthma
October 5th 2019Benralizumab is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid depletion of eosinophils via programmed cell death.
Read More
FDA Aims to Improve Oversight of Compounding Pharmacies with Data-Sharing System
October 4th 2019The FDA has awarded a cooperative agreement grant to the National Association of Boards of Pharmacy to develop a 3-year pilot project for a data-sharing system to improve oversight of compounding pharmacies.
Read More
Updated CAP Guidelines Narrows the Scope
October 3rd 2019The newly published guidelines answer 16 core questions about the diagnosis and treatment of CAP in adults. The guidelines are more narrow in scope than previous versions and focus primarily on the care of a patient with active pneumonia.
Read More
THC Products May Play a Role in Lung Injuries Associated with E-Cigarettes and Vaping
October 2nd 2019Findings published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) suggest that THC products are playing a role in the recent outbreak of lung injuries associated with e-cigarette and vape use.
Read More
NIH-Funded Research Centers Launched with Focus on Alzheimer Drug Development
October 2nd 2019The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.
Read More
Network of Research Centers Created for Development of Longer-Lasting Influenza Vaccines
October 1st 2019The National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institute of Health, has developed the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.
Read More
Fast Track Designation Granted for Relapsed/Refractory Myelofibrosis Treatment
October 1st 2019Officials from the FDA have granted Geron Corporation’s imetelstat fast track designation for adult patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.
Read More